Volume 34 Number 14 April 9-16, 2015
Antimicrobials, Vaccines, Interventions
Rates of vaccine evolution show strong effects of latency: implications for varicella zoster virus epidemiology.
Weinert LA et al. Mol. Biol. Evol. 2015 Apr (4) 1020-8
Weinert LA et al. Mol. Biol. Evol. 2015 Apr (4) 1020-8
Genetic analysis of invasive pneumococcal isolates from children in Ontario, Canada, 2007-2012.
Deng X et al. Pediatr. Infect. Dis. J. 2015 Mar 31.
Deng X et al. Pediatr. Infect. Dis. J. 2015 Mar 31.
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: An individual-patient- and sequence-level meta-analysis.
Rhee SY et al. PLoS Med. 2015 Apr (4) e1001810 (CDC Author)
Rhee SY et al. PLoS Med. 2015 Apr (4) e1001810 (CDC Author)
Phase 1 trials of rVSV Ebola vaccine in Africa and Europe - preliminary report.
Agnandji ST et al. N. Engl. J. Med. 2015 Apr 1. (CDC Author)
Agnandji ST et al. N. Engl. J. Med. 2015 Apr 1. (CDC Author)
Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.
Lai L et al. JAMA 2015 Mar 24-31 (12) 1249-55 (CDC Author)
Lai L et al. JAMA 2015 Mar 24-31 (12) 1249-55 (CDC Author)
Increase of RT-related transmitted drug resistance in non-CRF01_AE among HIV type 1-infected men who have sex with men in the 7 cities of China.
Zhao B et al. J. Acquir. Immune Defic. Syndr. 2015 Mar 1. (3) 250-5
Zhao B et al. J. Acquir. Immune Defic. Syndr. 2015 Mar 1. (3) 250-5
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire Chad E et al. Nature 2015 Apr 8.
Mire Chad E et al. Nature 2015 Apr 8.
No hay comentarios:
Publicar un comentario